Immunization by injection of live measles-virus vaccine, first marketed in 1963, has proven effective. Given at first with gamma globulin, the vaccine was further developed by 1965 so that one shot alone gives long-term, probably lifetime, immunity; a nationwide program was established in the United States for the vaccination of all children over the age of nine months.
Highly contagious viral childhood disease. It initially resembles a severe cold with red eyes and fever; a blotchy rash and higher fever later develop. After recovery, patients have lifelong immunity. Adult patients tend to have more severe cases. Antibiotics now prevent death from secondary infections. Measles itself, for which there is no drug, requires only bed rest, eye protection, and steam for bronchial irritation. A vaccine developed in the 1960s proved not to give permanent immunity and is too heat-sensitive for use in tropical areas. The worldwide incidence of measles continues to rise. Research is currently directed toward development of a more stable vaccine. Seealso rubella.
Learn more about measles with a free trial on Britannica.com.
Viral disease with a usually mild course, except in women in the first 20 weeks of pregnancy, in whom it can cause fetal birth defects (of eyes, heart, brain, and large arteries) or death. Sore throat and fever are followed by swollen glands and a rash. Up to 30percnt of infections may have no symptoms. Lifelong immunity follows infection. Encephalitis is a rare complication. Rubella was not distinguished from measles (rubeola) until the early 19th century and was not known to be dangerous until 1941. The virus was isolated in 1962, and a vaccine became available in 1969.
Learn more about rubella with a free trial on Britannica.com.
Measles is spread through respiration (contact with fluids from an infected person's nose and mouth, either directly or through aerosol transmission), and is highly contagious—90% of people without immunity sharing a house with an infected person will catch it. Airborne precautions should be taken for all suspected cases of measles.
The incubation period usually lasts for 4–12 days (during which there are no symptoms). Infected people remain contagious from the appearance of the first symptoms until 3–5 days after the rash appears.
Reports of measles go as far back to at least 600 B.C.E. however, the first scientific description of the disease and its distinction from smallpox is attributed to the Persian physician Ibn Razi (Rhazes) 860-932 who published a book entitled "The Book of Smallpox and Measles" (in Arabic: Kitab fi al-jadari wa-al-hasbah). In roughly the last 150 years, measles has been estimated to have killed about 200 million people worldwide. In 1954, the virus causing the disease was isolated from an 11-year old boy from the US, David Edmonston, and adapted and propagated on chick embryo tissue culture. To date, 21 strains of the measles virus have been identified. Licensed vaccines to prevent the disease became available in 1963.
The characteristic measles rash is classically described as a generalized, maculopapular, erythematous rash that begins several days after the fever starts. It starts on the head before spreading to cover most of the body, often causing itching. The rash is said to "stain", changing colour from red to dark brown, before disappearing.
Alternatively, laboratory diagnosis of measles can be done with confirmation of positive measles IgM antibodies or isolation of measles virus RNA from respiratory specimens. In cases of measles infection following secondary vaccine failure IgM antibody may not be present. However, in the rare case of a secondary vaccine failure, other external symptoms may be present, including nausea, headaches, or a feeling of slight dizzyness when turning one´s head to the left. In these cases serological confirmation may be made by showing IgG antibody rises by Enzyme immunoasay or complement fixation. In children, where phlebotomy is inappropriate, saliva can be collected for salivary measles specific IgA test. Adults are recommended to seek medical help right away.
Positive contact with other patients known to have measles adds strong epidemiological evidence to the diagnosis.
There is no specific treatment or antiviral therapy for uncomplicated measles. Most patients with uncomplicated measles will recover with rest and supportive treatment.
Some patients will develop pneumonia as a sequela to the measles. Histologically, a unique cell can be found in the paracortical region of hyperplastic lymph nodes in patients affected with this condition. This cell, known as the Warthin-Finkeldey cell, is a multinucleated giant with eosinophilic cytoplasmic and nuclear inclusions.
Patients with the measles should be placed droplet precautions.
Humans are the only known natural hosts of measles, although the virus can infect some non-human primate species.
The fatality rate from measles for otherwise healthy people in developed countries is low: approximately 1 death per thousand cases. In underdeveloped nations with high rates of malnutrition and poor healthcare, fatality rates of 10 percent are common. In immunocompromised patients, the fatality rate is approximately 30 percent.
In developed countries, most children are immunized against measles by the age of 18 months, generally as part of a three-part MMR vaccine (measles, mumps, and rubella). The vaccination is generally not given earlier than this because children younger than 18 months usually retain anti-measles immunoglobulins (antibodies) transmitted from the mother during pregnancy. A second dose is usually given to children between the ages of four and five, in order to increase rates of immunity. Vaccination rates have been high enough to make measles relatively uncommon. Even a single case in a college dormitory or similar setting is often met with a local vaccination program, in case any of the people exposed are not already immune. In developing countries, measles remains common.
Unvaccinated populations are at risk for the disease. After vaccination rates dropped in northern Nigeria in the early 2000s due to religious and political objections, the number of cases rose significantly, and hundreds of children died. A 2005 measles outbreak in Indiana was attributed to children whose parents refused vaccination. In the early 2000s the MMR vaccine controversy in the United Kingdom regarding a potential link between the combined MMR vaccine (vaccinating children from mumps, measles and rubella) and autism prompted a comeback in the measles party, where parents deliberately infect the child with measles to build up the child's immunity without an injection. This practice poses many health risks to the child, and has been discouraged by the public health authorities. Scientific evidence provides no support for the hypothesis that MMR plays a role in causing autism. However, the MMR scare in Britain caused uptake of the vaccine to plunge, and measles cases came back: 2007 saw 971 cases in England and Wales, the biggest rise in occurrence in measles cases since records began in 1995.
According to the World Health Organization (WHO), measles is a leading cause of vaccine preventable childhood mortality. Worldwide, the fatality rate has been significantly reduced by partners in the Measles Initiative: the American Red Cross, the United States Centers for Disease Control and Prevention (CDC), the United Nations Foundation, UNICEF and the World Health Organization (WHO). Globally, measles deaths are down 60 percent, from an estimated 873,000 deaths in 1999 to 345,000 in 2005. Africa has seen the most success, with annual measles deaths falling by 75 percent in just 5 years, from an estimated 506,000 to 126,000.
The joint press release by members of the Measles Initiative brings to light another benefit of the fight against measles: "Measles vaccination campaigns are contributing to the reduction of child deaths from other causes. They have become a channel for the delivery of other life-saving interventions, such as bed nets to protect against malaria, de-worming medicine and vitamin A supplements. Combining measles immunization with other health interventions is a contribution to the achievement of Millennium Development Goal Number 4: a two-thirds reduction in child deaths between 1990 and 2015."
Approximately 1000 cases of the disease were reported in Israel between August 2007 and May 2008 (in sharp contrast to just some dozen cases the year before). Many children in ultra-Orthodox Jewish communities were affected due to low vaccination coverage. As of 2008 the disease is endemic in the United Kingdom and epidemics have been reported in Austria, Italy and Switzerland. Low vaccination rates are responsible.
Between January 1 and April 25, 2008, a total of 64 confirmed measles cases were preliminarily reported in the United States to the Centers for Disease Control and Prevention, the most reported by this date for any year since 2001. Of the 64 cases, 54 were associated with importation of measles from other countries into the United States, and 63 of the 64 patients were unvaccinated or had unknown or undocumented vaccination status.
By July 9, 2008, a total of 127 cases were reported in 15 states (including 22 in Arizona), making it the largest US outbreak since 1997 (when 138 cases were reported). Most of the cases were acquired outside of the United States and afflicted individuals who had not been vaccinated.
By July 30, 2008, the number of cases had grown to 131. Of these, about half involved children whose parents rejected vaccination. The 131 cases occurred in 7 different outbreaks. There were no deaths, and 15 hospitalizations. 11 of the cases had received at least one dose of the measles vaccine. 122 of the cases involved children who were unvaccinated or whose vaccination status was unknown. Some of these were under the age of one year old, and so below the age when vaccination is recommended, but in 63 cases the vaccinations had been refused for religious or philosophical reasons. Many of the cases involved church groups and the home schooled.